Author information
Abstract
Agitation is a prevalent and difficult-to-treat symptom in patients with moderate-to-severe Alzheimer’s disease (AD). Though there are nonpharmacological and pharmacological interventions recommended for the treatment of agitation, the efficacy of these are modest and not always consistent. Furthermore, the safety profiles of currently prescribed medications are questionable. Nabilone, a synthetic cannabinoid, has a distinct pharmacological profile that may provide a safer and more effective treatment for agitation, while potentially having benefits for weight and pain. Additionally, emerging evidence suggests nabilone may have neuroprotective effects. We describe a clinical trial investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe AD. This will be a double-blind, randomized cross-over study comparing 6 weeks of nabilone (0.5-2 mg) and placebo, with a 1-week washout preceding each phase. Study outcomes will be measured at baseline and end of treatment for each treatment phase. The primary outcome measure will be agitation as assessed by the Cohen-Mansfield Agitation Inventory. The secondary outcomes include safety, behaviour (Neuropsychiatric Inventory), cognition (standardized Mini Mental Status Exam and either Severe Impairment Battery or Alzheimer’s disease Assessment Scale-Cognitive subscale) and global impression (Clinician’s Global Impression of Change). Exploratory outcomes include pain (Pain Assessment in Advanced AD), nutritional status (Mini-Nutritional Assessment-Short Form), caregiver distress (NPI caregiver distress), and blood-based biomarkers. A safe and efficacious pharmacological intervention for agitation, with effects on pain and weight loss in patients with moderate-to-severe AD could increase quality-of-life, reduce caregiver stress and avoid unnecessary institutionalization and related increases in health care costs.
CLINICAL TRIALS NUMBER:
KEYWORDS:
AD, Alzheimer’s disease, Agitation, Alzheimer’s disease, CB, cannabinoids, CB1, cannabinoid receptor 1, CB2, cannabinoidreceptor 2, CGIC, Clinician’s Global Impression of Change, CMAI, Cohen Mansfield Agitation Inventory, Cannabinoid, Clinical trial, EC50, half maximal effective concentration, FDA, Food and Drug Administration, IPA, International Psychogeriatric Association, LTC, long-term care, MAR, Medication Administration Record, MNA-SF, Mini-Nutritional Assessment-Short form, NPI-NH, Neuropsychiatric Inventory-Nursing home version, NPS, neuropsychiatric symptoms, Neuropsychiatric symptoms, PAINAD, Pain Assessment in Advanced AD, RCT, randomized controlled trial, SIB, Severe Impairment Battery, THC, tetrahydrocannabinol, sMMSE, standardized Mini-Mental Status Examination
- PMID: 31338476
- PMCID: PMC6627000
- DOI: 10.1016/j.conctc.2019.100385
